Indication
von Hippel-Lindau Syndrome
1 clinical trial
1 product
Clinical trial
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2026-03-29
Product
Belzutifan